Welcome to our dedicated page for OKYO Pharma Ordinary Shares news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO Pharma Ordinary Shares stock.
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for inflammatory eye diseases and chronic pain conditions. The company is at the forefront of creating innovative treatments for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP), both of which represent significant unmet medical needs in the ophthalmology sector.
One of OKYO Pharma's hallmark achievements is its development of the OK-101 ophthalmic solution. This drug candidate has shown promising results in pre-clinical studies, demonstrating dual-action anti-inflammatory and neuropathic corneal pain-reducing activities. The ongoing Phase 2 clinical trials are aimed at establishing the safety and efficacy of OK-101 in treating DED and NCP. Notably, these trials have successfully completed patient enrollment, with top-line results expected soon.
OKYO Pharma's approach leverages a unique membrane-anchored-peptide technology to ensure the prolonged presence of the drug in the ocular environment, thereby enhancing its therapeutic impact. In recent studies, OK-101 has exhibited statistically significant improvements in multiple dry eye-related symptoms, including stinging, burning, and blurred vision, as well as a notable reduction in conjunctival staining. These promising outcomes pave the way for future Phase 3 registration trials.
Financially, OKYO Pharma is well-positioned, with its ordinary shares listed on the NASDAQ Capital Market. The company continues to forge strategic partnerships and collaborations to bolster its research and development efforts. With a robust pipeline and a commitment to addressing the complex biology of eye diseases, OKYO Pharma stands as a pioneering entity in the biopharmaceutical landscape.
The latest developments include positive safety and efficacy results from the Phase 2 trials of OK-101, and the recent FDA clearance for OK-101's Investigational New Drug (IND) application for treating NCP. These milestones underscore the potential of OKYO Pharma's innovative solutions to significantly improve patient outcomes.
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, has announced a significant insider purchase. Gabriele Cerrone, the Executive Chairman, through Panetta Partners , acquired 50,000 ordinary shares at $1.03 per share on NASDAQ. This transaction has increased Cerrone's total shareholding to 9,851,570 shares, representing 29.12% of the company's issued share capital.
OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on innovative ocular therapies, has announced a significant insider purchase. The company's Executive Chairman, Gabriele Cerrone, through Panetta Partners , has acquired 80,000 ordinary shares at $1.15 per share on NASDAQ. This acquisition has increased Cerrone's total shareholding to 9,801,570 shares, representing 28.97% of the company's issued share capital.
OKYO Pharma specializes in developing treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.
OKYO Pharma (NASDAQ: OKYO) has been granted U.S. Patent No. 12,053,501 for its OK-101 drug, covering methods for treating symptoms of dry eye disease (DED). The patent, issued on August 6th, specifically addresses the use of OK-101 to treat irritated, burning eyes and blurred vision in DED patients. This development strengthens OKYO's intellectual property position in the multi-billion-dollar DED market.
OKYO Pharma is a clinical-stage biopharmaceutical company focusing on innovative ocular therapies for inflammatory DED and neuropathic corneal pain (NCP). The company's CEO, Dr. Gary S. Jacob, emphasized the importance of this patent in advancing their efforts to address unmet medical needs in ocular pain and inflammation treatment.
OKYO Pharma (NASDAQ: OKYO) announced that an interview with CEO Dr. Gary S. Jacob will air on Bloomberg TV's The RedChip Small Stocks, Big Money™ show on August 24, 2024, at 7 p.m. ET. The interview will provide a corporate update on OKYO's development of innovative therapies for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP).
OKYO's lead candidate, OK-101, a lipid-conjugated chemerin peptide, has shown promising results in a recent Phase 2 trial for DED, demonstrating improvements in symptoms and signs within 15 days with a favorable safety profile. The company is also targeting NCP, an ocular condition without FDA-approved treatments. OKYO has patent protection through 2039 and an experienced management team with a track record of successful clinical development and FDA approvals.
OKYO Pharma and SolarMax Technology are set to feature on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, August 24, at 7 p.m. ET. The show, available in an estimated 73 million U.S. homes, will air exclusive interviews with the CEOs of both companies.
OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharmaceutical company, is developing innovative therapies for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP). Their lead candidate, OK-101, showed promising results in a recent Phase 2 trial for DED, demonstrating improvements in symptoms and signs within 15 days.
SolarMax Technology (Nasdaq: SMXT), founded in 2008, has completed over 15,000 solar installations. The company is expanding its commercial solar development services in the U.S. market, with recent large-scale projects announced in Las Vegas and San Jose.
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, announced that its Executive Chairman, Gabriele Cerrone, has increased his stake in the company. Through Panetta Partners , an entity in which Cerrone has a beneficial interest, 50,000 ordinary shares were purchased on NASDAQ at $1.05 per share. This acquisition brings Cerrone's total shareholding to 9,721,570 shares, representing 28.73% of the company's issued share capital. OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP), targeting multi-billion-dollar markets.
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, has announced a significant insider purchase. Panetta Partners , an entity associated with Executive Chairman Gabriele Cerrone, acquired 35,000 ordinary shares of OKYO on NASDAQ at $1.00 per share. This transaction has increased Mr. Cerrone's total shareholding to 9,671,570 shares, representing 28.58% of the company's issued share capital.
OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. The company specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition without FDA-approved therapy.
OKYO's management will deliver a pre-recorded presentation available on-demand from 7:00 am EDT on the conference day. Interested parties can register for the conference and arrange virtual 1x1 meetings with OKYO's management through H.C. Wainwright representatives.
OKYO Pharma (NASDAQ: OKYO) has been granted a key European Patent for its OK-101 chemerin analogs and their method of use. This patent, titled 'Compositions Comprising Chemerin Analogs and Methods of Use', strengthens OKYO's intellectual property position in treating ocular inflammatory and pain conditions.
The company is developing innovative therapies for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), which currently lacks FDA-approved treatments. Dr. Gary S. Jacob, CEO of OKYO, emphasized the patent's importance in advancing novel therapies for ocular pain and inflammation. The company is exploring strategic partnerships to accelerate the development and commercialization of its pipeline candidates.
OKYO Pharma is set to begin a Phase 2 clinical trial of OK-101 for treating neuropathic corneal pain (NCP) in Q3 2024. This is the first instance of an FDA IND clearance for a drug targeting NCP, a significant unmet medical need. OK-101 has shown statistically significant pain relief in previous trials for dry eye disease and preclinical models of NCP. The 12-week, placebo-controlled trial will be led by Dr. Pedram Hamrah at Tufts Medical Center, involving 48 NCP patients. The study aims to measure pain improvement using a visual analogue scale (VAS).
CEO Dr. Gary S. Jacob emphasizes the potential of OK-101, highlighting its previous success in reducing pain in dry eye patients, some of whom suffer from NCP. The trial's design includes five study visits over 16 weeks, with pain improvement as the primary endpoint. Encouraging preclinical and clinical data support the trial's objectives. More details are available in the company's Form 6-K filing.
FAQ
What is the current stock price of OKYO Pharma Ordinary Shares (OKYO)?
What is the market cap of OKYO Pharma Ordinary Shares (OKYO)?
What is OKYO Pharma Limited known for?
What are the key products of OKYO Pharma?
What recent achievements has OKYO Pharma accomplished?
What is the significance of OK-101 in the treatment of Dry Eye Disease?
How is OKYO Pharma's financial condition?
What are the future plans for OK-101?
What is Dry Eye Disease (DED)?
What is Neuropathic Corneal Pain (NCP)?
How does OK-101 work?
Where can I find more information about OKYO Pharma?
